Cis-platinum clinical trials
Cis-platinum is named as an intervention in 40 current clinical trials in our Mexico, Canada, Israel, Australia, China, Norway, Japan, Singapore, Egypt, Ireland, Switzerland, India, Taiwan, Germany, France, Sweden and Poland registers. 20 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is National Cancer Institute (NCI) (22). The most-studied condition is Stage III Lung Cancer AJCC v8.
Patient leaflets for Cis-platinum
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Cis-platinum
40 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Cis-platinum
107 conditionsAll 107 conditions
| Condition (as registered) | Trials |
|---|---|
| Stage III Lung Cancer AJCC v8 | 4 |
| Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | 4 |
| Head and Neck Squamous Cell Carcinoma | 3 |
| Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | 3 |
| Head and Neck Cancer | 2 |
| Lung Non-Squamous Non-Small Cell Carcinoma | 2 |
| Stage II Lung Cancer AJCC v8 | 2 |
| Stage IIB Lung Cancer AJCC v8 | 2 |
| Bladder Urothelial Carcinoma | 2 |
| Stage II Bladder Cancer AJCC v8 | 2 |
| Stage IIIA Bladder Cancer AJCC v8 | 2 |
| Stage IV Nasopharyngeal Carcinoma AJCC v8 | 2 |
| Ganglioneuroblastoma, Nodular | 2 |
| Neuroblastoma | 2 |
| Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | 2 |
| Recurrent Hypopharyngeal Squamous Cell Carcinoma | 2 |
| Recurrent Laryngeal Squamous Cell Carcinoma | 2 |
| Advanced Head and Neck Squamous Cell Carcinoma | 1 |
| Advanced Hypopharyngeal Squamous Cell Carcinoma | 1 |
| Advanced Laryngeal Squamous Cell Carcinoma | 1 |
| Advanced Oropharyngeal Squamous Cell Carcinoma | 1 |
| Childhood Extracranial Germ Cell Tumor | 1 |
| Extragonadal Embryonal Carcinoma | 1 |
| Germ Cell Tumor | 1 |
| Malignant Germ Cell Tumor | 1 |
| Non-small Cell Lung Cancer Stage IIIB/IV | 1 |
| Head and Neck Squamous Cell Carcinoma (HNSCC) | 1 |
| Colorectal Adenocarcinoma | 1 |
| Advanced Solid Tumors | 1 |
| EBV Infection | 1 |
| Stage II Nasopharyngeal Carcinoma AJCC v7 | 1 |
| Stage III Nasopharyngeal Carcinoma AJCC v7 | 1 |
| Stage IVA Nasopharyngeal Carcinoma AJCC v7 | 1 |
| Advanced Non-Small Cell Lung Cancer | 1 |
| ENSAT Stage I Adrenal Cortex Carcinoma | 1 |
| ENSAT Stage II Adrenal Cortex Carcinoma | 1 |
| ENSAT Stage III Adrenal Cortex Carcinoma | 1 |
| Lung Non-Small Cell Carcinoma | 1 |
| Lung Non-Small Cell Squamous Carcinoma | 1 |
| Limited Stage Lung Small Cell Carcinoma | 1 |
| Stage I Lung Cancer AJCC v8 | 1 |
| Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | 1 |
| Stage II Lung Non-Small Cell Cancer AJCC v7 | 1 |
| Stage IIA Lung Cancer AJCC v8 | 1 |
| Muscle Invasive Bladder Carcinoma | 1 |
| Non-Muscle Invasive Bladder Urothelial Carcinoma | 1 |
| Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma | 1 |
| Stage I Bladder Cancer AJCC v8 | 1 |
| Stage II Nasopharyngeal Carcinoma AJCC v8 | 1 |
| Stage III Nasopharyngeal Carcinoma AJCC v8 | 1 |
| Locally Advanced Pancreatic Adenocarcinoma | 1 |
| Metastatic Pancreatic Adenocarcinoma | 1 |
| Stage III Pancreatic Cancer AJCC v8 | 1 |
| Stage IV Pancreatic Cancer AJCC v8 | 1 |
| Muscle Invasive Bladder Urothelial Carcinoma | 1 |
| Metastatic Nasopharyngeal Carcinoma | 1 |
| Recurrent Nasopharyngeal Carcinoma | 1 |
| Childhood Medulloblastoma | 1 |
| Childhood Hepatocellular Carcinoma | 1 |
| Childhood Malignant Liver Neoplasm | 1 |
| Fibrolamellar Carcinoma | 1 |
| Hepatoblastoma | 1 |
| Ganglioneuroblastoma | 1 |
| Advanced Bile Duct Carcinoma | 1 |
| Advanced Breast Carcinoma | 1 |
| Advanced Cervical Carcinoma | 1 |
| Advanced Endometrial Carcinoma | 1 |
| Advanced Vaginal Adenocarcinoma | 1 |
| Advanced Vaginal Adenosquamous Carcinoma | 1 |
| Advanced Vaginal Squamous Cell Carcinoma | 1 |
| Cervical Adenocarcinoma | 1 |
| Head and Neck Carcinoma of Unknown Primary | 1 |
| Locally Advanced Head and Neck Squamous Cell Carcinoma | 1 |
| Medulloblastoma | 1 |
| Locally Advanced Lung Non-Small Cell Carcinoma | 1 |
| Basaloid Squamous Cell Carcinoma | 1 |
| Oropharyngeal Squamous Cell Carcinoma | 1 |
| Stage III Bladder Cancer AJCC v8 | 1 |
| Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | 1 |
| Metastatic Head and Neck Squamous Cell Carcinoma | 1 |
| Metastatic Hypopharyngeal Squamous Cell Carcinoma | 1 |
| Metastatic Laryngeal Squamous Cell Carcinoma | 1 |
| Hypopharyngeal Squamous Cell Carcinoma | 1 |
| Laryngeal Squamous Cell Carcinoma | 1 |
| Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant | 1 |
| Human Papilloma Virus Infection | 1 |
| Stage III Squamous Cell Carcinoma of the Oropharynx | 1 |
| Stage IVA Squamous Cell Carcinoma of the Oropharynx | 1 |
| Stage IVB Squamous Cell Carcinoma of the Oropharynx | 1 |
| Recurrent Lung Non-Small Cell Carcinoma | 1 |
| Stage IIIA Lung Cancer AJCC v8 | 1 |
| Stage IIIB Lung Cancer AJCC v8 | 1 |
| Locally Advanced Cervical Adenocarcinoma | 1 |
| Locally Advanced Cervical Adenosquamous Carcinoma | 1 |
| Locally Advanced Cervical Squamous Cell Carcinoma | 1 |
| Stage IIIA Cervical Cancer FIGO 2018 | 1 |
| Recurrent Head and Neck Squamous Cell Carcinoma | 1 |
| Recurrent Oral Cavity Squamous Cell Carcinoma | 1 |
| Renal Pelvis and Ureter Urothelial Carcinoma | 1 |
| Stage II Gallbladder Cancer AJCC v8 | 1 |
| Stage IIA Gallbladder Cancer AJCC v8 | 1 |
| Stage IIB Gallbladder Cancer AJCC v8 | 1 |
| Stage III Gallbladder Cancer AJCC v8 | 1 |
| Neck Squamous Cell Carcinoma of Unknown Primary | 1 |
| Recurrent Laryngeal Verrucous Carcinoma | 1 |
| Lung Adenocarcinoma | 1 |
| Lung Large Cell Carcinoma | 1 |
Sponsors
lead sponsor per trialBy country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Cis-platinum trials
How many clinical trials are testing Cis-platinum?
40 current trials in our Mexico, Canada, Israel, Australia, China, Norway, Japan, Singapore, Egypt, Ireland, Switzerland, India, Taiwan, Germany, France, Sweden and Poland registers name Cis-platinum as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Cis-platinum trials recruiting patients?
Yes. 20 of the 40 trials are recruiting: 10 with sites in Mexico, 10 with sites in Canada, 7 with sites in Israel, 4 with sites in Australia, 3 with sites in China, 1 with sites in Norway, 1 with sites in Japan, 1 with sites in Singapore, 1 with sites in India, 1 with sites in Germany, 1 with sites in France, 1 with sites in Sweden and 1 with sites in Poland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Cis-platinum clinical trials?
National Cancer Institute (NCI) (22), NRG Oncology (5), Children's Oncology Group (5) and ECOG-ACRIN Cancer Research Group (3), among 9 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Cis-platinum clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Cis-platinum works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Cis-platinum works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cis-platinum (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.